Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q3 2023 Earnings Call Transcript

Mark Kirschbaum: Well, you know, we’re one patient away from finishing 6A. So I’m hoping that, that will be it. We have — the data looks very good. We have shown it. It seems to be doing what we want at those dose levels, so I’m hoping that this last page will conclude, and we’ll be able to formally announce. But until then, we don’t know.

Jonathan Aschoff: Okay. And Mark, there’s nothing telling you that you need to do any sort of slightly different dosing schedule, correct?

A –Mark Kirschbaum: No. We’re very happy as it says right now, but we can’t say anything until it is complete.

Operator: [Operator Instructions] We have no further questions in the queue at this time. I would now like to turn the call back over to the company for closing remarks.

Spiro Rombotis : Thank you, operator, and thanks to all of you for joining Cyclacel’s third quarter earnings call. Both our programs are approaching important catalysts such as starting Phase II proof-of-concept stage with a strong competitive profile in their therapeutic classes. As a reminder, our upcoming key milestones are: report final data from dose escalation stage and the RP2D determination from the 065-101 study of oral fadra in patients with advanced solid tumors and lymphoma; first patient dosed with oral fadra in Phase II stage of 065-101 study in patients with advanced solid tumors and lymphoma; report Phase I data from 140-101 study of oral plogosertib in patients with advanced solid tumors and lymphoma; and elaborate the novel mechanism of action of plogo. We look forward to providing you with further updates and hope to meet some of you at upcoming conferences. Operator, at this time, you may end the call.

Operator: This does conclude today’s program. Thank you for your participation. You may disconnect at any time.